Please use this identifier to cite or link to this item:
Title: Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs
Author: Espargaró Colomé, Alba
Medina, Aina
Di Pietro, Ornella
Muñoz-Torrero López-Ibarra, Diego
Sabaté Lagunas, Raimon
Keywords: Malaltia d'Alzheimer
Agregació (Química)
Disseny de medicaments
Alzheimer's disease
Aggregation (Chemistry)
Drug design
Issue Date: 22-Mar-2016
Publisher: Nature Publishing Group
Abstract: More than 46 million people worldwide suffer from Alzheimer's disease. A large number of potential treatments have been proposed; among these, the inhibition of the aggregation of amyloid β-peptide (Aβ), considered one of the main culprits in Alzheimer's disease. Limitations in monitoring the aggregation of Aβ in cells and tissues restrict the screening of anti-amyloid drugs to in vitro studies in most cases. We have developed a simple but powerful method to track Aβ aggregation in vivo in realtime, using bacteria as in vivo amyloid reservoir. We use the specific amyloid dye Thioflavin-S (Th-S) to stain bacterial inclusion bodies (IBs), in this case mainly formed of Aβ in amyloid conformation. Th-S binding to amyloids leads to an increment of fluorescence that can be monitored. The quantification of the Th-S fluorescence along the time allows tracking Aβ aggregation and the effect of potential antiaggregating agents.
Note: Reproducció del document publicat a:
It is part of: Scientific Reports, 2016, vol. 6, p. 23349
Related resource:
ISSN: 2045-2322
Appears in Collections:Articles publicats en revistes (Institut de Biomedicina (IBUB))
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))

Files in This Item:
File Description SizeFormat 
658740.pdf816.3 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons